FDA on Friday (April 19) approved the first generic naloxone nasal spray, commonly known as Narcan, for use in a community setting by people who do not have medical training. Moving forward, the agency also plans to prioritize review of applications for generic overdose-reversal drugs. While it’s unclear when the generic naloxone nasal spray, which is manufactured by Teva Pharmaceuticals, will be available on the market, the agency says the approval is a crucial step for the agency as it...